GYRE
Gyre TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
GYRE vs peer average
62/100
GYRE vs. peer average (C vs. D)
Grade spread
A 1 · B 1 · C 2 · D 3 · F 4
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
ALT is the first available peer comparator.
Loose same-sector small-cap biopharma comp for event-driven trading and regulatory optionality; useful for sentiment framing, not a direct operating analog.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
GYRE
Gyre Therapeutics
ALT
Altimmune
Grade
C
D
Momentum
61
66
Value
43
41
Sentiment
63
-
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Defensive
Grade position vs ALT
GYRE / ALT
Grade Position
In line
GYRE vs. peer average (C vs. D)
62/100
Momentum
61
ALTValue
43
GYRESentiment
63
-Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs GYRE
ALT is the first peer returned for this comparison set.